Acelyrin reported positive results from global phase 3 trial of izokibep in HS

Acelyrin, Inc., a late-stage clinical biopharmaceutical company, announced encouraging results from its global phase 3 clinical trial of izokibep for patients with moderate-to-severe hidradenitis suppurativa (HS). The trial showed statistically significant and clinically meaningful improvements across various efficacy endpoints, particularly in higher-order responses such as HiSCR90 and HiSCR100 by the 12-week mark.

Izokibep is a small protein therapeutic designed to inhibit IL-17A with high potency due to its strong binding affinity and small molecular size—about one-tenth that of a monoclonal antibody—which allows for robust tissue penetration. Its albumin binding domain also helps extend its half-life. The treatment is under evaluation in several late-stage trials for moderate-to-severe HS, psoriatic arthritis (PsA), and noninfectious uveitis. Previous phase 3 data for HS and PsA have shown clinical responses comparable to next-generation IL-17 inhibitors. Acelyrin had previously announced it would cease internal development of izokibep for HS and PsA.